RLAY as reported
Relay Therapeutics, Inc. reported $10M of revenue over the trailing twelve months, +24% on the year before. 8 reported series are charted on this page, each one as filed.
$10M
Revenue, trailing twelve months · to Q2 2026 · +24% against the twelve months before
- Net Income
- −$286M
Net Income · −8.2% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$236M
Free Cash Flow · trailing twelve months to Q4 2025
- EPS
- −$1.56
EPS · −19% year on year · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $10M | +24% | Q2 2026 |
| Net Income | −$286M | −8.2% | Q2 2026 |
| EPS | −$1.56 | −19% | Q2 2026 |
| Op Margin | −40743% | n/a | Q3 2023 · 11 quarters behind |
| Net Margin | −37854% | n/a | Q3 2023 · 11 quarters behind |
| ROE | −43% | n/a | Q2 2026 |
| ROA | −39% | n/a | Q2 2026 |
| Free Cash Flow | −$236M | n/a | Q4 2025 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Relay Therapeutics, Inc. (RLAY) - Revenue & ProfitRevenue & ProfitRelay Therapeutics, Inc. (RLAY)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com